table_1.docx
Human cytomegalovirus (HCMV) co-infection is highly prevalent within HIV-1 cohorts and is an important cofactor in driving ongoing immune activation, even during effective antiretroviral treatment. HCMV infection has recently been associated with expansion of adaptive-like natural killer (NK) cells, which harbor epigenetic alterations that impact on their cellular function and phenotype. The influence of HCMV co-infection on the considerable heterogeneity among NK cells and their functional responses to different stimuli was assessed in a cohort of HIV-1-infected individuals sampled during different stages of infection, compared with healthy subjects stratified according to HCMV serostatus. Our data demonstrate a reshaping of the NK cell pool in HIV-1 infection of HCMV-seropositive individuals, with an accentuated peripheral transition of CD56dim NK cells toward a mature CD57+ CD85j+ NKG2C+ NKG2A− phenotype. Lack of PLZF further distinguishes adaptive NK cells from other NK cells expressing CD57 or NKG2C. PLZF− NK cells from HIV-infected individuals had high expression of CD2, were Siglec-7 negative and exhibited downregulation of key signaling molecules, SYK and FcεRI-γ, overwhelmingly displaying features of adaptive NK cells that correlated with HCMV serum Ab levels. Notably this adaptive-like signature was detected during early HIV-1 infection and persisted during treatment. Adaptive-like NK cell subsets in HIV-1-infected individuals displayed enhanced IFN-γ production following Fc receptor triggering compared with their conventional NK cell counterparts, and their ability to produce TNF-α and degranulate was preserved. Together, these data suggest that HMCV infection/reactivation, a hallmark of HIV-1 infection, plays a role in driving a relative expansion of NK cells with adaptive features during HIV-1 infection. The identification of selective NK subsets with retained effector activity in HIV-1-infected subjects raises the possibility of developing therapeutic strategies that exploit specific NK subpopulations to achieve better HIV-1 control.
History
References
- https://doi.org//10.1056/NEJM198906293202605
- https://doi.org//10.1038/nri3174
- https://doi.org//10.1016/j.coviro.2015.10.008
- https://doi.org//10.1016/j.immuni.2015.09.013
- https://doi.org//10.1038/ni.3227
- https://doi.org//10.1038/ng934
- https://doi.org//10.1038/ng2035
- https://doi.org//10.1084/jem.20070695
- https://doi.org//10.1016/j.chom.2010.10.008
- https://doi.org//10.1016/j.it.2016.01.005
- https://doi.org//10.1038/nature07665
- https://doi.org//10.1073/pnas.1110900108
- https://doi.org//10.1182/blood-2011-10-386995
- https://doi.org//10.1086/504719
- https://doi.org//10.1016/j.immuni.2015.02.008
- https://doi.org//10.1016/j.celrep.2016.04.005
- https://doi.org//10.1182/blood-2012-10-459545
- https://doi.org//10.4049/jimmunol.1302053
- https://doi.org//10.1016/j.immuni.2015.02.013
- https://doi.org//10.4049/jimmunol.1203034
- https://doi.org//10.1182/blood-2008-05-157354
- https://doi.org//10.1093/infdis/jiu417
- https://doi.org//10.1007/s11904-016-0297-9
- https://doi.org//10.3389/fimmu.2017.01322
- https://doi.org//10.1097/00002030-200309050-00005
- https://doi.org//10.1038/nbt.2594
- https://doi.org//10.1073/pnas.2336091100
- https://doi.org//10.3389/fimmu.2017.00699
- https://doi.org//10.1073/pnas.0409872102
- https://doi.org//10.1182/blood-2005-03-1100
- https://doi.org//10.1086/509811
- https://doi.org//10.1128/JVI.02614-15
- https://doi.org//10.1371/journal.pone.0011966
- https://doi.org//10.1111/imm.12239
- https://doi.org//10.4049/jimmunol.1402448
- https://doi.org//10.3389/fimmu.2017.00731
- https://doi.org//10.1016/j.jaci.2016.04.025
- https://doi.org//10.1074/jbc.274.48.34089
- https://doi.org//10.1182/blood-2009-06-226332
- https://doi.org//10.1089/AID.2017.0095
- https://doi.org//10.1182/blood-2011-08-372003
- https://doi.org//10.1186/1742-4690-10-154
- https://doi.org//10.1038/srep45319
- https://doi.org//10.1073/pnas.0813192106
- https://doi.org//10.1128/JVI.02666-08
- https://doi.org//10.1182/blood-2012-04-425397
- https://doi.org//10.3389/fimmu.2017.01033
- https://doi.org//10.1038/leu.2015.260
- https://doi.org//10.3389/fimmu.2017.01176
- https://doi.org//10.3389/fimmu.2017.00054
- https://doi.org//10.1089/AID.2011.0253
Usage metrics
Read the peer-reviewed publication
Categories
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity